Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058215 | 0.88 | KMT2A (0.70) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL5584812 | 0.85 | KMT2A (0.65) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL9057396 | 0.85 | KMT2A (0.65) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL31191977 | 0.82 | KMT2A (0.49) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL7932429 | 0.80 | KMT2A (0.46) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL20839726 | 0.80 | KMT2A (0.46) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL5584972 | 0.79 | KMT2A (0.59) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL20839735 | 0.77 | KMT2A (0.43) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL31191940 | 0.77 | KMT2A (0.43) | KMT2ANPC1RAB9AMAPTPOLB | |
| SCHEMBL7921949 | 0.77 | KMT2A (0.43) | KMT2ANPC1RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703358-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | China Pharmaceutical University (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260021103-A1 | IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025092775-A1 | PHTHALAZINONE GSPT1 PROTEIN DEGRADING AGENT AND USE THEREOF | 中国药科大学 | 2025-05-08 | — | — | WO | disclosed |
| CN-119912437-A | Phthalazinone GSPT protein degradation agent and application thereof | 中国药科大学 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024222918-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | 中国药科大学 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024059107-A1 | IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2019057969-A1 | DUAL AGONISTS OF FXR AND PPARδ AND THEIR USES | Johann Wolfgang Goethe-Universität (DE) | 2019-03-28 | — | — | WO | disclosed |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. | 2004-02-26 | — | — | US | disclosed |
| US-6492390-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS. | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | disclosed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021103-A1 | IKZF2 AND CK1-ALPHA DEGRADING COMPOUNDS AND USES THEREOF | IKZF1, CSNK1A1, CKS1B | KMT2A 213/4885NPC1 1207/4885RAB9A 2663/4885 |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | PTGS1, IL1R1, PTGES2 | KMT2A 3828/4885NPC1 3367/4885RAB9A 3922/4885 |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | PTGS1, PTGES2, IL1R1 | KMT2A 2680/4885NPC1 3015/4885RAB9A 4276/4885 |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | FNTB, PGLS, EP300 | KMT2A 3579/4885NPC1 386/4885RAB9A 1274/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | KMT2A 765/4885NPC1 2906/4885RAB9A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.